Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
01.04.2025 05:00:27
|
Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib
(RTTNews) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 million, under the licensing agreement signed in December 2023.
In December 2023, Abbisko Therapeutics entered into an exclusive licensing agreement with Merck regarding pimicotinib, a CSF-1R inhibitor. Under the terms of the Agreement, Merck initially had an exclusive license to commercialize pimicotinib for all indications in the Chinese mainland, Hong Kong, Macau and Taiwan with an exclusive option for global commercial rights of pimicotinib.
Merck now has exercised such option and has the exclusive license to commercialize pimicotinib worldwide. Abbisko Therapeutics has already received the one-time, non-refundable upfront payment of US$70.0 million in February 2024, and is now entitled to receive the additional option exercise fee of US$85.0 million.
Additionally, Merck has the option to co-develop pimicotinib for additional indications under certain conditions. In total, Abbisko Therapeutics is eligible to receive up to US$605.5 million in payments, including upfront, development, and commercial milestones, as well as double-digit percentage royalties on annual net sales.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
17.10.25 |
Merck beugt sich dem Druck der Trump-Regierung (Spiegel Online) | |
15.10.25 |
Handel in New York: Dow Jones liegt am Mittag im Plus (finanzen.at) | |
15.10.25 |
Freundlicher Handel: Zum Start Gewinne im Dow Jones (finanzen.at) | |
15.10.25 |
Erste Schätzungen: Merck öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
14.10.25 |
Börse New York: Dow Jones klettert am Nachmittag (finanzen.at) | |
14.10.25 |
Dow Jones 30 Industrial-Titel Merck-Aktie: So viel Gewinn hätte ein Investment in Merck von vor 5 Jahren eingefahren (finanzen.at) | |
13.10.25 |
Dow Jones aktuell: Dow Jones beendet die Sitzung im Plus (finanzen.at) | |
13.10.25 |
Gewinne in New York: Dow Jones am Montagnachmittag mit Zuschlägen (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 72,40 | 0,42% |
|